市場調査レポート

肺動脈高血圧症 (PAH) の世界市場 (プロスタサイクリン、プロスタサイクリンアナログ、ERA、PDE-5阻害剤、sGC刺激剤、Selexipag) - 業界分析、規模、シェア、成長、動向および予測 (2014〜2020年)

Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

発行 Transparency Market Research 商品コード 329319
出版日 ページ情報 英文 73 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
肺動脈高血圧症 (PAH) の世界市場 (プロスタサイクリン、プロスタサイクリンアナログ、ERA、PDE-5阻害剤、sGC刺激剤、Selexipag) - 業界分析、規模、シェア、成長、動向および予測 (2014〜2020年) Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日: 2015年04月16日 ページ情報: 英文 73 Pages
概要

肺動脈高血圧症 (PAH) は、血液を心臓から肺に送る肺動脈における高血圧で、肺動脈が狭くなるとき、あるいは閉塞したときに起こる非常に珍しい症状です。

当レポートでは、肺動脈高血圧症 (PAH) 市場の現状と将来的見通しについて調査し、2012〜2020年の予測、市場動向と今後の見通し、参入企業のプロファイルなどをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 世界の肺動脈高血圧症 (PAH) 市場概要

  • イントロダクション
  • 疫学
  • 米国における様々なPAH治療薬による年間治療費
  • 市場促進因子
  • 市場阻害因子
  • 機会
  • イベント影響分析
  • 競合環境

第4章 薬剤クラス別市場

  • 概要
  • プロスタサイクリン、プロスタサイクリンアナログ
  • エンドセリン受容体拮抗薬 (ERA)
  • ホスホジエステラーゼ5 (PDE-5) 阻害剤
  • 可溶性グアニル酸シクラーゼ (sGC) 刺激剤

第5章 パイプライン分析

  • 概要
  • 早期段階薬剤候補
  • 後期段階薬剤候補

第6章 地域別市場

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第7章 提言

  • 研究開発への注力
  • 連携
  • 途上国の標的化

第8章 企業プロファイル

  • Actelion Pharmaceuticals, Ltd.
  • Bayer HealthCare
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer, Inc.
  • United Therapeutics Corporation
目次

Pulmonary arterial hypertension (PAH) is a progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs. The research study has been divided into eight chapters namely, preface, executive summary, global PAH market overview, global PAH market revenue by drug class, PAH market pipeline analysis, global PAH market revenue by geography, recommendations, and company profiles.

The executive summary chapter covers a market snapshot representing key findings from the study on the global PAH market. The market overview chapter of the report comprises qualitative analysis of the overall PAH market, considering factors determining market dynamics such as growth drivers, restraints, and opportunities. This chapter also includes a section on epidemiology of PAH. A section on the event impact analysis has also been provided in the market overview chapter of the report on the PAH market. In the competitive landscape section, the market revenue share of key players operating in the PAH market in terms of percentage in 2013 has been provided. The market share analysis of key players involved a study of the company's product/service portfolio and sales revenue along with the geographical presence.

In chapter four, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators, based on the commercially-available drug classes, to treat PAH. The market revenue size for each segment has been provided in terms of USD million in the chapter for the period from 2012 to 2020, along with the CAGR for the forecast period between 2014 and 2020, considering 2012 and 2013 as the base years. The chapter also provides qualitative analysis for each segment, based on factors such as market trends, recent developments, future outlook, and opportunities.

Chapter five deals with the pipeline analysis of the PAH market and comprises information such as major steps involved in the development and commercialization of a drug, tabular presentation of early-stage drug candidates, and extensive analysis and future sales projection of the late-stage drug candidate, Uptravi (selexipag).

Geographically, the global PAH market has been classified into four major regions namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market size and forecast for each of these regions along with the CAGR has been provided in the report.

The study on the global PAH market also suggests a list of recommendations for new companies aspiring to enter the market and existing companies willing to accentuate revenue shares. The report concludes with the profiles of major players in the global PAH market such as Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation. Each company profile in the report provides information under the heads: company overview, financial overview, product portfolio, business strategies, and recent developments.

The company overview section comprises basic information about the company such as major business areas, company's brief history and its establishment year, number of employees, and geographical presence. In the financial overview section, annual revenue for the last three consecutive years (2011, 2012, and 2013) has been provided. The business strategies section mentions key strategies adopted by a company in the past to strengthen its position in the PAH market. The recent developments section shares information about the recent activities of the companies operating in the PAH market.

The global PAH market is segmented as follows:

Global Pulmonary Arterial Hypertension Market, by Drug Class

  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators

Pipeline Analysis: Pulmonary Arterial Hypertension Market

  • Early-stage Drug Candidates (Phase I & Phase II)
  • Late-stage Drug Candidates (Phase III & Registration Phase)

Global Pulmonary Arterial Hypertension Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 - Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Assumptions
    • 1.3.2. Sources
      • 1.3.2.1. Secondary Research
      • 1.3.2.2. Primary Research
    • 1.3.3. Models
  • 1.4. List of Abbreviations

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Global Pulmonary Arterial Hypertension Market (2013 & 2020)
  • 2.2. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019 (USD Million)
  • 2.3. Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2013 & 2020 (Value %)

Chapter 3 - Global Pulmonary Arterial Hypertension (PAH) Market Overview

  • 3.1. Introduction
  • 3.2. Epidemiology
  • 3.3. Annual Treatment Cost with Various PAH Drugs in the United States
  • 3.4. Drivers
    • 3.4.1. Newly-approved therapeutic agents will significantly contribute to the growth of the PAH market
    • 3.4.2. Governments encouraging development of orphan drugs to propel growth of the PAH market
  • 3.5. Restraints
    • 3.5.1. Patent expirations of major PAH drugs during the forecast period
  • 3.6. Opportunities
    • 3.6.1. Emphasis on developing breakthrough therapy for the treatment of PAH
  • 3.7. Even Impact Analysis
  • 3.8. Competitive Landscape
    • 3.8.1. Global Pulmonary Arterial Hypertension Market Share Analysis, by Key Players, 2013 (Value %)

Chapter 4 - Global Pulmonary Arterial Hypertension (PAH) Market Revenue, by Drug Class

  • 4.1. Overview
    • 4.1.1. Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2012 - 2020 (USD Million)
    • 4.1.2. Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2013 & 2020 (Value %)
  • 4.2. Prostacyclin and Prostacyclin Analogs
    • 4.2.1. Global Prostacyclin and Prostacyclin Analogs Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.2. Historical Sales Data: Prostacyclin and Prostacyclin Analog Brands
  • 4.3. Endothelin Receptor Antagonists (ERAs)
    • 4.3.1. Global Endothelin Receptor Antagonists Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.2. Historical Sales Data: Endothelin Receptor Antagonist Brands
  • 4.4. Phosphodiesterase 5 (PDE-5) Inhibitors
    • 4.4.1. Global Phosphodiesterase 5 Inhibitors Market Revenue, 2012 - 2020 (USD Million)
    • 4.4.2. Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands
  • 4.5. Soluble Guanylate Cyclase (sGC) Stimulators
    • 4.5.1. Global Soluble Guanylate Cyclase Stimulators Market Revenue, 2014 - 2020 (USD Million)

Chapter 5 - Pipeline Analysis: Global Pulmonary Arterial Hypertension (PAH) Market

  • 5.1. Overview
    • 5.1.1. Major Steps: Drug Development and Commercialization
  • 5.2. Early-stage Drug Candidates (Phase I & Phase II)
    • 5.2.1. Pulmonary Arterial Hypertension: Phase I & Phase II Molecules
  • 5.3. Late-stage Drug Candidates (Phase III & Registration Phase)
    • 5.3.1. Uptravi (selexipag)
      • 5.3.1.1. Global Uptravi (selexipag) Market Revenue, 2016 - 2020 (USD Million)

Chapter 6 - Global Pulmonary Arterial Hypertension (PAH) Market, By Geography

  • 6.1. Overview
    • 6.1.1. Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • 6.5. Rest of the World (RoW)
    • 6.5.1. RoW Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 - Recommendations

  • 7.1. Focus on research and development
  • 7.2. Collaboration
  • 7.3. Targeting developing nations

Chapter 8. - Company Profiles

  • 8.1. Actelion Pharmaceuticals, Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
    • 8.1.5. Recent Developments
  • 8.2. Bayer HealthCare
    • 8.2.1. Company Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategies
    • 8.2.5. Recent Developments
  • 8.3. Gilead Sciences, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategies
    • 8.3.5. Recent Developments
  • 8.4. GlaxoSmithKline plc
    • 8.4.1. Company Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategies
    • 8.4.5. Recent Developments
  • 8.5. Novartis International AG
    • 8.5.1. Company Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategies
    • 8.5.5. Recent Developments
  • 8.6. Pfizer, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategies
    • 8.6.5. Recent Developments
  • 8.7. United Therapeutics Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Financial Overview
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategies
    • 8.7.5. Recent Developments

List of Figures

  • FIG. 1: Pulmonary Arterial Hypertension (PAH): Market Segmentation
  • FIG. 2: Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019 (USD Million)
  • FIG. 3: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2013 & 2020 (Value %)
  • FIG. 4: Global Pulmonary Arterial Hypertension Market Share Analysis, by Key Players, 2013 (Value %)
  • FIG. 5: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2013 & 2020 (Value %)
  • FIG. 6: Global Prostacyclin and Prostacyclin Analogs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 7: Global Endothelin Receptor Antagonists Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 8: Global Phosphodiesterase 5 Inhibitors Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 9: Global Soluble Guanylate Cyclase Stimulators Market Revenue, 2014 - 2020 (USD Million)
  • FIG. 10: Major Steps: Drug Development and Commercialization
  • FIG. 11: Global Uptravi (selexipag) Market Revenue, 2016 - 2020 (USD Million)
  • FIG. 12: North America Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13: Europe Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14: Asia Pacific Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15: RoW Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16: Actelion Pharmaceuticals, Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 17: Bayer HealthCare: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 18: Gilead Sciences, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 19: GlaxoSmithKline plc: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 20: Novartis International AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 21: Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 22: United Therapeutics Corporation: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1: List of Abbreviations
  • TABLE 2: Market Snapshot: Global Pulmonary Arterial Hypertension Market (2013 & 2020)
  • TABLE 3: Annual Treatment Cost with Various PAH Drugs in the United States
  • TABLE 4: Event Impact Analysis: Global PAH Market
  • TABLE 5: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2012 - 2020 (USD Million)
  • TABLE 6: Historical Sales Data: Prostacyclin and Prostacyclin Analog Brands
  • TABLE 7: Historical Sales Data: Endothelin Receptor Antagonist Brands
  • TABLE 8: Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands
  • TABLE 9: Pulmonary Arterial Hypertension: Phase I & Phase II Molecules
  • TABLE 10: Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • TABLE 11: List of Major Countries in North America
  • TABLE 12: List of Major Countries in Europe
  • TABLE 13: List of Major Countries in Asia Pacific
  • TABLE 14: List of Major Countries in Rest of the World
Back to Top